Showing results (51-60 of 156) with videos related to
Sort By:
Pageof 16
Breast Cancer Research and Treatment|January 1, 1992
Cellular effects of tamoxifen in primary breast cancerJ F Robertson, I O Ellis, R I Nicholson, et al.British Journal of Cancer|July 5, 2006
Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cellsH E Jones, J M W Gee, D Barrow, et al.The Journal of Steroid Biochemistry and Molecular Biology|December 20, 1990
Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancerR I Nicholson, K J Walker, R A McClelland, et al.Lancet (London, England)|August 11, 1979
Relationship of oestrogen-receptor status to survival in breast cancerH M Bishop, R W Blamey, C W Elston, et al.European Journal of Cancer & Clinical Oncology|March 1, 1989
Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapyJ F Robertson, M R Williams, J Todd, et al.The British Journal of Surgery|September 1, 1986
Survival patterns in hormone treated advanced breast cancerM R Williams, J H Todd, R I Nicholson, et al.British Journal of Cancer|November 1, 1990
Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survivalA R Dixon, J F Robertson, L Jackson, et al.International Journal of Cancer|June 11, 1997
New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145H E Jones, C M Dutkowski, D Barrow, et al.Breast Cancer Research and Treatment|January 1, 1994
Biological factors of prognostic significance in locally advanced breast cancerJ F Robertson, I O Ellis, D Pearson, et al.British Journal of Cancer|September 1, 1981
Oestrogen-receptor status and sites of metastasis in breast cancerF C Campbell, R W Blamey, C W Elston, et al.Pageof 16